A detailed history of Ubs Group Ag transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Group Ag holds 359,569 shares of NBIX stock, worth $49.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
359,569
Previous 316,927 13.45%
Holding current value
$49.1 Million
Previous $43.6 Million 5.12%
% of portfolio
0.01%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $4.89 Million - $6.53 Million
42,642 Added 13.45%
359,569 $41.4 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $10.6 Million - $11.6 Million
81,301 Added 34.5%
316,927 $43.6 Million
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $12 Million - $13.2 Million
91,732 Added 63.75%
235,626 $32.5 Million
Q4 2023

Feb 09, 2024

BUY
$106.07 - $132.76 $1.02 Million - $1.28 Million
9,655 Added 7.19%
143,894 $19 Million
Q3 2023

Nov 09, 2023

BUY
$94.02 - $117.1 $1.03 Million - $1.28 Million
10,938 Added 8.87%
134,239 $15.1 Million
Q2 2023

Aug 11, 2023

SELL
$89.53 - $104.87 $118,627 - $138,952
-1,325 Reduced 1.06%
123,301 $11.6 Million
Q1 2023

May 12, 2023

SELL
$94.11 - $123.02 $8.67 Million - $11.3 Million
-92,172 Reduced 42.52%
124,626 $12.6 Million
Q4 2022

Feb 08, 2023

BUY
$106.72 - $127.06 $6.9 Million - $8.22 Million
64,678 Added 42.52%
216,798 $25.9 Million
Q3 2022

Nov 10, 2022

BUY
$92.03 - $107.81 $6.29 Million - $7.37 Million
68,323 Added 81.53%
152,120 $16.2 Million
Q2 2022

Aug 10, 2022

SELL
$75.79 - $100.07 $10.7 Million - $14.2 Million
-141,449 Reduced 62.8%
83,797 $8.17 Million
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $44,194 - $57,834
-610 Reduced 0.27%
225,246 $21.1 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $4.31 Million - $5.75 Million
54,141 Added 31.53%
225,856 $19.2 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $2.61 Million - $3 Million
30,328 Added 21.45%
171,715 $16.5 Million
Q2 2021

Aug 13, 2021

BUY
$89.43 - $102.27 $4.43 Million - $5.06 Million
49,514 Added 53.89%
141,387 $13.8 Million
Q1 2021

May 12, 2021

BUY
$87.57 - $119.4 $6.68 Million - $9.1 Million
76,245 Added 487.87%
91,873 $8.94 Million
Q4 2020

Feb 11, 2021

SELL
$86.91 - $108.33 $48,408 - $60,339
-557 Reduced 3.44%
15,628 $1.5 Million
Q3 2020

Nov 12, 2020

SELL
$96.16 - $135.15 $4.14 Million - $5.82 Million
-43,031 Reduced 72.67%
16,185 $1.56 Million
Q2 2020

Jul 31, 2020

BUY
$85.09 - $130.36 $776,020 - $1.19 Million
9,120 Added 18.21%
59,216 $7.23 Million
Q1 2020

May 01, 2020

SELL
$75.11 - $113.76 $1.87 Million - $2.84 Million
-24,952 Reduced 33.25%
50,096 $4.34 Million
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $2.58 Million - $3.52 Million
-29,711 Reduced 28.36%
75,048 $8.07 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $6.12 Million - $7.41 Million
73,000 Added 229.86%
104,759 $9.44 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $856,694 - $1.08 Million
-11,859 Reduced 27.19%
31,759 $2.68 Million
Q1 2019

May 14, 2019

SELL
$69.31 - $91.53 $7.22 Million - $9.54 Million
-104,174 Reduced 70.49%
43,618 $3.84 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $7.22 Million - $13.1 Million
105,626 Added 250.5%
147,792 $10.6 Million
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $3.09 Million - $3.93 Million
31,256 Added 286.49%
42,166 $5.18 Million
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $3.79 Million - $5.33 Million
-50,319 Reduced 82.18%
10,910 $1.07 Million
Q1 2018

May 15, 2018

BUY
$75.88 - $92.43 $2.85 Million - $3.48 Million
37,618 Added 159.32%
61,229 $5.08 Million
Q4 2017

Feb 14, 2018

BUY
$58.53 - $77.59 $1,229 - $1,629
21 Added 0.09%
23,611 $1.83 Million
Q3 2017

Nov 14, 2017

SELL
$47.97 - $61.28 $525,847 - $671,751
-10,962 Reduced 31.73%
23,590 $1.45 Million
Q2 2017

Aug 14, 2017

SELL
N/A
-9,910 Reduced 22.29%
34,552 $1.59 Million
Q1 2017

Nov 14, 2017

BUY
N/A
44,462
44,462 $1.93 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.